Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Jefferies Group issued their Q3 2017 EPS estimates for Halozyme Therapeutics in a research note issued on Wednesday. Jefferies Group analyst E. Yang anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter. Jefferies Group currently has a “Underperform” rating and a $7.00 price objective on the stock. Jefferies Group also issued estimates for Halozyme Therapeutics’ Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($1.01) EPS, FY2019 earnings at ($0.58) EPS, FY2020 earnings at ($0.40) EPS and FY2021 earnings at ($0.13) EPS.
A number of other equities analysts have also commented on the stock. BidaskClub raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Zacks Investment Research lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 3rd. Barclays PLC reaffirmed an “overweight” rating and set a $16.00 price target on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. BMO Capital Markets started coverage on shares of Halozyme Therapeutics in a research report on Monday, April 17th. They set a “market perform” rating and a $14.00 price target on the stock. Finally, ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $14.75.
ILLEGAL ACTIVITY NOTICE: This report was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://transcriptdaily.com/2017/08/13/jefferies-group-comments-on-halozyme-therapeutics-inc-s-q3-2017-earnings-halo.html.
Halozyme Therapeutics (HALO) opened at 11.90 on Friday. The firm’s market capitalization is $1.59 billion. Halozyme Therapeutics has a 52-week low of $8.18 and a 52-week high of $15.20. The firm has a 50-day moving average of $13.12 and a 200-day moving average of $13.12.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. Halozyme Therapeutics’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) earnings per share.
A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $10,026,000. Teachers Advisors LLC raised its position in Halozyme Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 726,329 shares of the biopharmaceutical company’s stock valued at $7,176,000 after buying an additional 5,285 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $215,000. Macquarie Group Ltd. raised its position in Halozyme Therapeutics by 50.9% in the fourth quarter. Macquarie Group Ltd. now owns 460,000 shares of the biopharmaceutical company’s stock valued at $4,545,000 after buying an additional 155,200 shares in the last quarter. Finally, Parametrica Management Ltd purchased a new position in Halozyme Therapeutics during the first quarter valued at approximately $212,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.